LogicBio Therapeutics

Fred Chereau, CEO
Lexington, MA
(NASDAQ: LOGC)
LogicBio Therapeutics is a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients with significant unmet medical needs using GeneRide™, its proprietary technology platform. GeneRide enables the site-specific integration of a therapeutic transgene in a nuclease-free and promoterless approach by relying on the native process of homologous recombination to drive potential lifelong expression. LogicBio is committed to developing medicines that will transform the lives of pediatric patients and their families.
www.logicbio.com



By using this website you agree to accept our Privacy Policy and Terms & Conditions